PER 0.00% 8.2¢ percheron therapeutics limited

Bioshares Report stated"to date no serious adverse events...

  1. 13,187 Posts.
    lightbulb Created with Sketch. 1395
    Bioshares Report stated"to date no serious adverse events related to the treatment have been reported in the ANP Phase 2  trial.If the trial results are good then ANP will activate licensing discussions with potential partners"
    This report was released just after the Interim results re Acromegaly.

    Well here we are.as many have said that anp already have the report.
    Pfizer will protect their market share.(somavert)

    I cannot see Anp selling the whole company for under a $1.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
0.000(0.00%)
Mkt cap ! $73.92M
Open High Low Value Volume
8.0¢ 8.2¢ 8.0¢ $111.7K 1.386M

Buyers (Bids)

No. Vol. Price($)
1 31160 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 21976 1
View Market Depth
Last trade - 16.10pm 28/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.